Sumatriptan succinate (Imitrex): Dr. Reddy's Launched Authorized Generic

Dr. Reddy's Labs announced (Here) that it has launched the authorized generic version of GlaxoSmithKline's Imitrex® (sumatriptan succinate) tablets 25mg, 50mg, and 100mg in the United States. Dr. Reddy's is the first company to launch an authorized generic version of Imitrex® tablets in the US market.
In October 2006, the Company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline Imitrex® tablets. The specific financial terms and conditions of the settlement have not been disclosed.
Eralier, innovator settled with generic companies like Ranbaxy and Dr. Reddy’s by allowing an authorized generic version to these two companies. Ranbaxy will launch its authorized generic version in December 2008. Another generic players Cobalt will launch its product in first quarter of 2009 ie before the expiry of US5037845 (Expiry: Feb 6, 2009): which covers Sumatriptan as product.
GlaxoSmithKline Imitrex® tablets, which are indicated for the acute treatment of migraine attacks in adults, had U.S. sales of $1.29 billion for the 12 month period ending December, 2007 according to IMS.